These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 38234594)

  • 21. Functional involvement of central cholinergic circuits and visual hallucinations in Parkinson's disease.
    Manganelli F; Vitale C; Santangelo G; Pisciotta C; Iodice R; Cozzolino A; Dubbioso R; Picillo M; Barone P; Santoro L
    Brain; 2009 Sep; 132(Pt 9):2350-5. PubMed ID: 19584099
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Charles Bonnet Syndrome in Patients with Open-Angle Glaucoma: Prevalence and Correlation to Visual Field Loss.
    Peters D; Molander S; Lomo T; Singh A
    Ophthalmol Glaucoma; 2022; 5(3):337-344. PubMed ID: 34688955
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical and cognitive correlates of visual hallucinations in dementia with Lewy bodies.
    Cagnin A; Gnoato F; Jelcic N; Favaretto S; Zarantonello G; Ermani M; Dam M
    J Neurol Neurosurg Psychiatry; 2013 May; 84(5):505-10. PubMed ID: 23264688
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hallucinations and other psychotic experiences across diagnoses: A comparison of phenomenological features.
    Schutte MJL; Linszen MMJ; Marschall TM; Ffytche DH; Koops S; van Dellen E; Heringa SM; Slooter AJC; Teunisse R; van den Heuvel OA; Lemstra AW; Foncke EMJ; Slotema CW; de Jong J; Rossell SL; Sommer IEC
    Psychiatry Res; 2020 Oct; 292():113314. PubMed ID: 32731082
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Visual hallucinations in Parkinson and Charles Bonnet Syndrome patients. A phenomenological and pathogenetic comparison].
    Diederich NJ; Pieri V; Goetz CG
    Fortschr Neurol Psychiatr; 2000 Mar; 68(3):129-36. PubMed ID: 10758844
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk factors for visual hallucinations in patients with Parkinson's disease.
    Gama RL; de Bruin VM; de Bruin PF; Távora DG; Lopes EM; Jorge IF; Bittencourt LR; Tufik S
    Neurol Res; 2015 Feb; 37(2):112-6. PubMed ID: 25002179
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence and risk factors for visual hallucinations in Chinese patients with Parkinson's disease.
    Zhu J; Shen B; Lu L; Lan W; Pan Y; Zhang L; Dong J; Wang M; Zhang L
    J Neurol Sci; 2017 Jan; 372():471-476. PubMed ID: 27823833
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Investigation of structural brain changes in Charles Bonnet Syndrome.
    Firbank MJ; daSilva Morgan K; Collerton D; Elder GJ; Parikh J; Olsen K; Schumacher J; Ffytche D; Taylor JP
    Neuroimage Clin; 2022; 35():103041. PubMed ID: 35576854
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Caudate dopaminergic denervation and visual hallucinations: evidence from a ¹²³I-FP-CIT SPECT study.
    Kiferle L; Ceravolo R; Giuntini M; Linsalata G; Puccini G; Volterrani D; Bonuccelli U
    Parkinsonism Relat Disord; 2014 Jul; 20(7):761-5. PubMed ID: 24787757
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Frequency, prevalence, incidence and risk factors associated with visual hallucinations in a sample of patients with Parkinson's disease: a longitudinal 4-year study.
    Gibson G; Mottram PG; Burn DJ; Hindle JV; Landau S; Samuel M; Hurt CS; Brown RG; M Wilson KC
    Int J Geriatr Psychiatry; 2013 Jun; 28(6):626-31. PubMed ID: 22927195
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hallucinatory experiences in visually impaired individuals: Charles Bonnet syndrome - implications for research and clinical practice.
    Jurišić D; Sesar I; Ćavar I; Sesar A; Živković M; Ćurković M
    Psychiatr Danub; 2018 Jun; 30(2):122-128. PubMed ID: 29930220
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Complex visual hallucinations in the visually impaired, the Charles Bonnet syndrome].
    Molander S; Singh A
    Lakartidningen; 2019 Jan; 116():. PubMed ID: 30667516
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Visual hallucinations.
    Weil RS; Lees AJ
    Pract Neurol; 2021 May; ():. PubMed ID: 33986117
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Executive functions are impaired in patients with Parkinson's disease with visual hallucinations.
    Barnes J; Boubert L
    J Neurol Neurosurg Psychiatry; 2008 Feb; 79(2):190-2. PubMed ID: 18202206
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neural network models for DMT-induced visual hallucinations.
    Schartner MM; Timmermann C
    Neurosci Conscious; 2020; 2020(1):niaa024. PubMed ID: 33343929
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Case Report and Review: Charles Bonnet Syndrome Plus With Dementia.
    Kompella S; Kaushal S; Khan SA; Alvarez Villalba CL
    HCA Healthc J Med; 2022; 3(1):23-28. PubMed ID: 37426870
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Deep-Dream Virtual Reality Platform for Studying Altered Perceptual Phenomenology.
    Suzuki K; Roseboom W; Schwartzman DJ; Seth AK
    Sci Rep; 2017 Nov; 7(1):15982. PubMed ID: 29167538
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Imagine that: cholinesterase inhibitor treatment of complex visual hallucinations of unknown aetiology.
    Salih Y; De Angelis A; Poole NA
    Cogn Neuropsychiatry; 2021 Sep; 26(5):335-342. PubMed ID: 34142635
    [No Abstract]   [Full Text] [Related]  

  • 39. Ventral striatal dopaminergic defect is associated with hallucinations in Parkinson's disease.
    Jaakkola E; Joutsa J; Mäkinen E; Johansson J; Kaasinen V
    Eur J Neurol; 2017 Nov; 24(11):1341-1347. PubMed ID: 28834102
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.